A £9.4 million collaborative research centre, involving researchers from the NIHR Nottingham Biomedical Research Centre and led by the University of Nottingham, will accelerate improved tests, treatments and potentially cures for thousands of people living with rare respiratory diseases.
The LifeArc Centre for Rare Respiratory Diseases will unite children, adults and families with clinical experts, researchers, investors and industry leaders. The centre’s experts will work in collaboration, aiming to overcome some of the barriers that can prevent new tests and treatments reaching patients with rare diseases.
Globally, there are more than 300 million people living with rare diseases, of which one in 20 are related to respiratory conditions. While rare on their own, collectively they create significant social and economic costs.
The centre is a partnership between Universities and NHS Trusts, co-led by Edinburgh with partners in Nottingham, Dundee, Cambridge, Southampton and at University College London. It is supported by six other clinical partners in Belfast, Cardiff, Leeds, Leicester, Manchester and at Royal Brompton.
The collaboration will create a UK-wide bank of anonymised tissue samples and models of disease, allowing researchers to advance pioneering therapies. It will work to lower the risk of investment in rare respiratory disease research, building the partnerships and innovative infrastructure needed for clinical trials in patients with rare conditions. The centre team also aims to boost public awareness of the realities of living with rare respiratory diseases and raise patient awareness of resources that can improve their quality of life.
The centre, funded by the not-for-profit medical research charity LifeArc, is led by Professor Kev Dhaliwal, Professor of Healthcare Technology at the University of Edinburgh’s Institute for Regeneration and Repair and Honorary Consultant in Respiratory Medicine at the Royal Infirmary of Edinburgh, NHS Lothian.
It is supported by patient groups including Action for Pulmonary Fibrosis, Childhood Interstitial Lung Disease, LAM Action, PCD Research and PCD Support UK.
Professor Kev Dhaliwal, LifeArc Centre for Rare Respiratory Diseases, said:
“Patients and their families are at the heart of our centre. By bringing together the four UK nations’ community of researchers, patient groups, clinical experts, NHS trusts and by coalescing industry, investors and wonderful colleagues around the world, we are sharing resources and committed to developing new therapies for everyone afflicted with rare lung disease. We are very grateful to LifeArc for supporting the centre on our journey of collaboration across the UK with a mission and purpose to innovate and translate for patient benefit.
Professor Simon Johnson, Director of the UK centres for Lymphangioleiomyomatosis (LAM) and Rare Cystic Lung Diseases based at the University of Nottingham, will co-lead the LifeArc centre, said:
Rare diseases are often poorly recognised by doctors and difficult for researchers to study. This funding from LifeArc is a major boost for UK rare lung disease research that will raise the profile of rare diseases, reduce diagnostic errors and enable the development of treatments for these currently incurable conditions.”
Former BBC News journalist and presenter, Philippa Thomas, has the rare incurable lung disease, LAM. Philippa’s condition has stabilised but for many people, the disease can be severely life-limiting. Philippa explains:
There is so little research funding for rare respiratory diseases, that getting treatment - let alone an accurate diagnosis - really does feel like a lottery. It is also terrifying being diagnosed with something your GP will never have heard of. I am one of the lucky patients not to be relying on bottles of oxygen or surviving with a lung transplant. I’ve only had a kidney tumour removed and one lung pinned in place. But even as a woman living a relatively normal life with LAM, I am overjoyed at the prospect of a new LifeArc centre for Rare Respiratory Diseases. It represents new and significant hope for all RRD patients and their families - hope that we can speed up and bring together the provision of essential information, access to specialised care, new clinical trials, and above all a future with a cure.”
Rare disease research can be fragmented, with scientists and stakeholders lacking access to the specialist facilities, advice and resources needed to deliver new innovations to patients.
Rare disease research can be fragmented, with scientists and stakeholders lacking access to the specialist facilities, advice and resources needed to deliver new innovations to patients.
The LifeArc Centre for Rare Respiratory Diseases is one of four new centres to be funded by the non-profit medical charity LifeArc, seeking to address these issues.
Dr Catriona Crombie, Head of Rare Disease at LifeArc, said:
We’re extremely proud to be launching four new LifeArc Translational Centres for Rare Diseases. Each centre has been awarded funding because it holds real promise for delivering change for people living with rare diseases. These centres also have the potential to create a blueprint for accelerating improvements across other disease areas, including common diseases.
Story credits
About LifeArc
LifeArc is a self-funded, non-profit medical research organisation. We take science ideas out of the lab and help turn them into medical breakthroughs that can be life-changing for patients. We have been doing this for more than 25 years and our work has resulted in five licensed medicines and a diagnostic for antibiotic resistance.
Our teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. Our work is in translational science – bridging the gap between academic research and clinical development, providing funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives.
LifeArc, a charity registered in England and Wales under 1015243 and in Scotland under SC037861